Form SCHEDULE 13D/A - General Statement of Acquisition of Beneficial Ownership: [Amend]
SEC Accession No. 0001415889-25-022496
Filing Date
2025-08-20
Accepted
2025-08-20 17:18:40
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13D/A  
1 primary_doc.xml SCHEDULE 13D/A 44549
  Complete submission text file 0001415889-25-022496.txt   46314
Mailing Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932
Business Address 100 CAMPUS DRIVE, SUITE 102 FLORHAM PARK NJ 07932 (877) 742-8466
Phathom Pharmaceuticals, Inc. (Subject) CIK: 0001783183 (see all company filings)

EIN.: 824151574 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A | Act: 34 | File No.: 005-91182 | Film No.: 251237753
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304
Business Address 1001 PAGE MILL ROAD BUILDING 4, SUITE B PALO ALTO CA 94304 650-325-5156
Frazier Life Sciences Public Fund, L.P. (Filed by) CIK: 0001863769 (see all company filings)

EIN.: 862999645 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13D/A